GlassScriptPhysician profile
Kelly O'Brien
NPI 1558731638
$810.84
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $589 · 2022: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $352.69 | 2021-2022 | |
| Abbvie INC. | $238.98 | 2021-2022 | |
| Urovant Sciences INC | $77.62 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $38.41 | 2021-2022 | |
| Myovant Sciences INC. | $36.22 | 2021 | |
| Evofem Biosciences, INC. | $20.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.05 | 2021 | |
| Exeltis, USA INC. | $16.32 | 2021 | |
| Avion Pharmaceuticals | $13.20 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly O'Brien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.